Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
Open Access
- 16 January 2021
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 10 (4), 44-49
- https://doi.org/10.17650/2222-1468-2020-10-4-44-49
Abstract
Dermal toxicity of anti-cancer drugs apparent in patients with thyroid cancer. This side effect appears, in particular, in relation to increased administration of targeted anti-cancer treatment, especially tyrosinkinase inhibitors, towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumor cell. Our article focuses on the dermatotoxity, designated also as skin reaction, which most frequently occurs in patients treated by tyrosinkinase inhibitors – sorafenib, vandetonib, cabozantinib and lenvantinib. High prevalence of dermatotoxity, reported by patients, treated with these drugs underscores the need for greater understanding of the pathogenesis and management of this syndrome.Keywords
This publication has 16 references indexed in Scilit:
- Cabozantinib in Progressive Medullary Thyroid CancerJournal of Clinical Oncology, 2013
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinibDermatologic Therapy, 2011
- Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson ExperienceJournal of Clinical Endocrinology & Metabolism, 2010
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2010
- Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibBritish Journal of Dermatology, 2009
- Phase II Trial of Sorafenib in Metastatic Thyroid CancerJournal of Clinical Oncology, 2009
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?European Journal of Cancer, 2006